Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma

被引:11
作者
Huang, Jianfeng [1 ]
Zou, Qinzhou [1 ]
Qian, Danqi [1 ]
Zhou, Leyuan [1 ]
Yang, Bo [1 ]
Chu, Jianjun [1 ]
Pang, Qingfeng [2 ]
Wang, Kewei [2 ]
Zhang, Fuzheng [1 ]
机构
[1] Jiangnan Univ, Dept Radiat Oncol, Affiliated Hosp, 200 Huihe Rd, Wuxi 214062, Jiangsu, Peoples R China
[2] Jiangnan Univ, Wuxi Med Sch, Dept Epidemiol, 1800 Lihu Ave, Wuxi 214122, Jiangsu, Peoples R China
关键词
nasopharyngeal carcinoma; intensity-modulated radiotherapy; nimotuzumab; concurrent chemoradiotherapy; treatment outcome; RECEPTOR MONOCLONAL-ANTIBODY; SQUAMOUS-CELL CARCINOMA; OPEN-LABEL; PHASE-II; CETUXIMAB; COMBINATION; SURVIVAL; CISPLATIN; OUTCOMES; TRIAL;
D O I
10.2147/OTT.S151554
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective: This study aimed to evaluate the safety and efficacy of intensity-modulated radiotherapy (IMRT) plus nimotuzumab with or without concurrent chemotherapy (CCT) for patients with locally advanced nasopharyngeal carcinoma (LA-NPC). Patients and methods: A total of 50 newly diagnosed patients with LA-NPC treated at the Affiliated Hospital of Jiangnan University between November 2011 and January 2017 were retrospectively analyzed. All patients received the combined treatment modality of nimotuzumab plus IMRT. Nimotuzumab was administered concurrently with IMRT at a weekly dose of 200 mg. Neoadjuvant, concurrent or adjuvant chemotherapy with the doublet regimen of taxanes (docetaxel or paclitaxel) plus platinum (cisplatin or nedaplatin) were administered. Among the 50 patients, 43 (86.0%) received >= 6 cycles of nimotuzumab (median 7 cycles, range 2-14 cycles) and 29 (58.0%) received two cycles of CCT with docetaxel plus nedaplatin. Results: With a median follow-up of 28.0 months, the 2-year progression-free survival (PFS) and overall survival were 83.29% (95% confidence interval [CI]: 67.93%-91.72%) and 97.67% (95% CI: 84.62%-99.67%), respectively. Both univariate and multivariate analyses revealed that cycles of nimotuzumab were significantly associated with PFS. Patients who received >= 6 cycles of nimotuzumab showed a better PFS than those receiving,6 cycles (P=0.006), whereas the addition of CCT failed to improve PFS. Oral mucositis was the most common adverse event, which was recorded as grade 3-4 in 18 (36.0%) patients. Besides, two (4.0%) patients experienced nimotuzumab-related anaphylaxis, and no skin rash was found in any patient. Subgroup analysis revealed that the patients who received CCT had more grade 3-4 adverse events as compared to those who did not receive CCT (62.1% vs 33.3%, P=0.045). Conclusion: The regime of nimotuzumab plus IMRT for the treatment of LA-NPC was well tolerated, with encouraging survival data, and it could be an effective treatment alternative for patients with LA-NPC. Further clinical trials are needed to confirm these findings.
引用
收藏
页码:5835 / 5841
页数:7
相关论文
共 27 条
[1]   Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis [J].
Blanchard, Pierre ;
Lee, Anne ;
Marguet, Sophie ;
Leclercq, Julie ;
Ng, Wai Tong ;
Ma, Jun ;
Chan, Anthony T. C. ;
Huang, Pei-Yu ;
Benhamou, Ellen ;
Zhu, Guopei ;
Chua, Daniel T. T. ;
Chen, Yong ;
Mai, Hai-Qiang ;
Kwong, Dora L. W. ;
Cheah, Shie Lee ;
Moon, James ;
Tung, Yuk ;
Chi, Kwan-Hwa ;
Fountzilas, George ;
Zhang, Li ;
Hui, Edwin Pun ;
Lu, Tai-Xiang ;
Bourhis, Jean ;
Pignon, Jean Pierre .
LANCET ONCOLOGY, 2015, 16 (06) :645-655
[2]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[3]   Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].
Bonner, James A. ;
Harari, Paul M. ;
Giralt, Jordi ;
Cohen, Roger B. ;
Jones, Christopher U. ;
Sur, Ranjan K. ;
Raben, David ;
Baselga, Jose ;
Spencer, Sharon A. ;
Zhu, Junming ;
Youssoufian, Hagop ;
Rowinsky, Eric K. ;
Ang, K. Kian .
LANCET ONCOLOGY, 2010, 11 (01) :21-28
[4]   Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial [J].
Chan, ATC ;
Teo, PML ;
Ngan, RK ;
Leung, TW ;
Lau, WH ;
Zee, B ;
Leung, SF ;
Cheung, FY ;
Yeo, W ;
Yiu, HH ;
Yu, KH ;
Chiu, KW ;
Chan, DT ;
Mok, T ;
Yuen, KT ;
Mo, F ;
Lai, M ;
Kwan, WH ;
Choi, P ;
Johnson, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) :2038-2044
[5]   Nasopharyngeal carcinoma [J].
Chua, Melvin L. K. ;
Wee, Joseph T. S. ;
Hui, Edwin P. ;
Chan, Anthony T. C. .
LANCET, 2016, 387 (10022) :1012-1024
[6]   Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients [J].
Crombet, T ;
Osorio, M ;
Cruz, T ;
Roca, C ;
del Castillo, R ;
Mon, R ;
Iznaga-Escobar, N ;
Figueredo, R ;
Koropatnick, J ;
Renginfo, E ;
Fernández, E ;
Alvárez, D ;
Torres, O ;
Ramos, M ;
Leonard, I ;
Pérez, R ;
Lage, A .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1646-1654
[7]   Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma [J].
Feng, Hui-Xia ;
Guo, Su-Ping ;
Li, Gui-Rong ;
Zhong, Wen-Huan ;
Chen, Liu ;
Huang, Li-Ru ;
Qin, Hui-Ying .
MEDICAL ONCOLOGY, 2014, 31 (09) :1-6
[8]   Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results [J].
He, Xia ;
Xu, Jianhua ;
Guo, Wenjie ;
Jiang, Xuesong ;
Wang, Xue ;
Zong, Dan .
FUTURE ONCOLOGY, 2013, 9 (10) :1459-1467
[9]   Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial [J].
Huang, Jian-feng ;
Zhang, Fu-zheng ;
Zou, Qin-zhou ;
Zhou, Le-yuan ;
Yang, Bo ;
Chu, Jian-jun ;
Yu, Jia-hua ;
Zhang, Hao-wen ;
Yuan, Xiao-peng ;
Tai, Guo-mei ;
Liu, Fen-ju ;
Ma, C-M Charlie .
ONCOTARGET, 2017, 8 (02) :2457-2465
[10]  
Huang Xiao-dong, 2007, Zhonghua Zhongliu Zazhi, V29, P197